Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

ANNOUNCEMENT OF PROPOSAL TO CONCLUDE A PRIVATE PLACEMENT AND A MARKET UPDATE

New strategic shareholder Synergia Life Sciences Pvt. Ltd, based in India, a long-time partner and supplier of NattoPharma, has expressed interest to become a significant shareholder in NattoPharma, by investing MNOK 7,0 directly in the company. Through discussions with the Board, the negotiated share price for a transaction is NOK 12,50. After the completion of a private placement of 560 000 new shares, Synergia will be a 3,1% shareholder and the 7th largest. To facilitate and execute this transaction, the board will invite the shareholders to an extraordinary general assembly, since

Changes to the composition of Nordax’s Nomination Committee

As a consequence of the ownership changes that have taken place since Nordax’s Nomination Committee was appointed in September 2017, the composition of Nordax’s Nomination Committee has changed. Robert Furuhjelm representing Nordic Capital Fund VIII through Cidron Humber Ltd and Ricard Wennerklint representing Sampo plc. take seats on the Nomination Committee, while the representatives of Lannebo Fonder and SEB Investment Management resign from the Nomination Committee.According to the principles for the appointment of the Nomination Committee, adopted by the AGM, the three largest

Interim report third quarter 2017

The leading Nordic fuel cell company PowerCell Sweden AB (publ)  presents interim report for the third quarter of 2017. A developed market strategy and reinforcements of the sales organization have made sales almost four times higher than the corresponding quarter of 2016, resulting in a reduced operating loss.The commercialisation and industrialisation of PowerCell is progressing with full speed. The company has prioritised four market segments with high customer interest and many quotation requests. This resulted in almost fourfold sales compared to the

Axactor closed first transaction in partnership with Geveran Trading Co. Ltd.

Axactor has reach an agreement with one of the leading financial institutions to execute a large primary transaction in Spain. The portfolio can be split into 3 distinct segments, one is composed of unsecured NPL's with an outstanding balance of close to EUR300m across more than 11.000 cases. The second segment contains in excess of EUR94m in secured NPL's across circa 150 cases and finally the third segment contains roughly 450 Real Estate Owned assets with an Appraisal Value of around EUR40m. This combined transaction will be one of the largest portfolios acquired by Axactor and is of a

Acting General Counsel appointed

NCC has appointed Ann-Marie Hedbeck as new acting Legal Counsel, member of the Executive Management Team and Secretary of the Board. Ann-Marie Hedbeck replaces NCC’s current General Counsel Håkan Broman, who has assumed the position of acting President and CEO of NCC since October 30.“Ann-Marie Hedbeck has solid legal qualifications and extensive experience of executive management and Board work at listed companies. I am very pleased that from day one Ann-Marie Hedbeck can take over my duties as General Counsel so that I can focus fully on my obligations as Acting CEO,” says Håkan Broman,

Read original

Ripasso Energy carries out a new share issue in the amount of SEK 91.7 million - Strengthens the PWR BLOK initiative and reprioritises resources

The market response in the wake of the launch of the PWR BLOK proved to be very positive, and potentially significantly larger than the company’s initial assessment. For this reason, Ripasso Energy has today decided to raise additional resources for the PWR BLOK by: · resolving to carry out an issue of no more than 18,347,312 shares at a price of SEK 5 per share, which would provide the company with SEK 91.7 million before issue costs, if the issue is fully subscribed. The issue has already garnered subscription commitments in a total amount of approximately SEK 58 million, or around 63%

The sale of Apetit’s seafood business to Insula AS completed

Apetit Plc, Stock Exchange Release on 1 November 2017 at 09:30 a.m.   Apetit Plc announced on 29 June 2017, that it had signed an agreement on selling its seafood business in Finland, Sweden and Norway to Insula AS. The requirements of closing the sale have been fulfilled and the transaction has been completed as of 1 November 2017.    Apetit Plc   Juha VanhainenCEO    For more information, please contact:Juha Vanhainen, CEO, tel. +358 10 402 00    Copies to:Nasdaq HelsinkiMain mediawww.apetitgroup.fi/en

SolunoBC a real Super Company – four years running!

Soluno Business Communications, formerly SolusBC, has won the title of Super Company for four consecutive years. “When you think that only a tiny percentage of Sweden’s companies find their way onto the Super Company list, it is totally amazing that we have once again made the list,” says Soluno’s CEO, Mattias Ohde.The Super Company award is presented jointly by the business information company Bisnode and the Swedish business publication Veckans Affärer. The selection is based on extremely tough criteria for the financial performance of all Swedish limited liability companies over the past

Axactor Q3 2017 - Continues to deliver on strategy, with rapid development and growth

Highlights third Quarter of 2017 - Continued positive operational performance and to grow the business.  - Signed and closed a co-investment partnership with Geveran Trading Co. Limited, with a EUR 300 million investment capacity.  - Future growth opportunities fueled by additional funding facilities from the banks, in addition to the partnership with Geveran. - Gross Revenue of EUR 23.6 million (11.1) - EBITDA of EUR 2.0 million (-0.8) - Cash EBITDA at EUR 6.2 million (-0.1)  - Net result positive with EUR 0.3 million (-2.1) Axactor continued to show positive

New date for Sectra’s nine-month interim report 2017/2018

Linköping, Sweden – November 1, 2017 – The Board of Directors of international medical imaging IT and cybersecurity company Sectra  (SECT-B.ST) has decided to change the publication date of the company’s nine-month interim report for the 2017/2018 fiscal year. The new date is Monday, March 12, 2018, at 8:00 a.m. (previous planned publication date was March 6, 2018).The change was made due to the fact that the original report date coincides with important industry trade fairs that management need to attend.  Sectra’s financial reporting calendar

ASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEAL

1 November 2017 07:00 GMT ASTRAZENECA AND ASPEN COMPLETE AGREEMENT FORRESIDUAL RIGHTS TO ANAESTHETIC MEDICINES AstraZeneca today announced that it has completed the commercialisation agreement  (announced 14 September 2017) with Aspen Global Incorporated (AGI), part of the Aspen Group, under which AGI has acquired the residual rights to established anaesthetic medicines comprising of Diprivan, EMLA, Xylocaine/Xylocard/

KONE a top climate change performer with an A- score in CDP 2017

KONE Corporation, trade press release, November 1, 2017 KONE, a global leader in the elevator and escalator industry, has been recognized for its actions and strategies in response to climate change. The company has received a score of A- on climate action and is in the top category for advancing environmental stewardship. The score ranges from A to D, with A the best possible rating, and is based on independent assessment against the scoring criteria of CDP, an international not-for-profit organization that drives sustainable economies. KONE is proud to have reported in CDP

Record-breaking cruise season in Copenhagen

The cruise season was a successful one for Copenhagen Malmö Port, CMP. Copenhagen welcomed 850,000 passengers, setting a new record. CMP is now investing in continued growth. A new terminal is being built in Copenhagen, and as from April 2018 Visby will form part of CMP’s cruise operations.Cruise operations continue to have the wind in their sails. As the figures for 2017 are added up, CMP has welcomed 325 ships and 850,000 passengers to Copenhagen. This is a new passenger record, which is partly the result of the ships becoming bigger and bigger. “Last season we welcomed 15 larger ships,

AstraZeneca tralokinumab update in severe asthma

This announcement contains inside information 1 November 2017 07:00 GMT ASTRAZENECA PROVIDES UPDATE ON TRALOKINUMAB PHASE III PROGRAMME IN SEVERE, UNCONTROLLED ASTHMA AstraZeneca and its global biologics research and development arm, MedImmune, today announced the top-line results of the Phase III STRATOS 2 and TROPOS trials for tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, in severe, uncontrolled asthma. In STRATOS 2, tralokinumab did not achieve a statistically-significant reduction in the annual asthma exacerbation rate (AAER), the primary endpoint,

Skanska builds replacement schools in Cincinnati, USA, for USD 65M, about SEK 560M

Skanska has, in a joint venture with Megen Construction, signed a contract with the Winton Woods City School District and the Ohio Facilities Construction Commission to manage a multi-building construction project in Cincinnati, Ohio, USA. The total contract is worth USD 93M. Skanska will include its 70 percent share of the contract worth USD 65M, about  SEK 560M, in the US order bookings for the fourth quarter 2017.The project includes two new replacement schools: a 19,000-square-meter, elementary school, and a 22,000-square-meter middle and high school. Both projects will seek a minimum

As is society, so is the apartment building

YIT Corporation News, November 1, 2017 at 09:00 a.m.The history of apartment buildings in independent Finland is a tale of social change. Equal rights, urbanisation, economic fluctuations and the rise of environmentalism are all visible in the buildings of their time. The 1880s saw the rise of the first apartment buildings in the Finland´s largest cities.  The construction of apartment buildings underwent several changes in early 20th century, during the time Finland sought and claimed its independence. In the early 1900s, reinforced concrete revolutionised the industry and

Vicore Pharma to Attend Two Investor Conferences in London in November 2017

Vicore Pharma will present at the Biotech and Money Inv€$tival Showcase in partnership with Jefferies and host one-to-one meetings at the Jefferies 2017 London Healthcare ConferenceVicore Pharma Holding (publ) (ticker:VICO), announced today that its CEO, Per Jansson, is scheduled to present at the Biotech and Money Inv€$tival showcase on Tuesday, November 14, 2017, at the Waldorf Hilton Hotel in London, UK at 1:45 p.m. GMT and will attend the Jefferies 2017 London Healthcare Conference, November 15-16, 2017, also at the Waldorf Hilton Hotel in London. Vicore Pharma’s CEO, Per Jansson,

Stora Enso to divest Puumerkki, a wholesaler of wooden building materials

STORA ENSO OYJ INVESTOR NEWS 1 November 2017 at 9.00 EETStora Enso has divested 100% of its shares in the Finnish Puumerkki Oy and the Estonian Puumerkki AS to Mimir Invest AB, a global investment firm. Puumerkki is a specialised wholesaler of wooden building materials and was 100% owned by Stora Enso. This divestment supports Stora Enso’s Wood Products division in focusing on its growth strategy and further build on the strength of the premium portfolio of products and services. Puumerkki’s wholesale business does not belong to Stora Enso’s core business. The new owner is in a better

PRESS RELEASE: VTT to develop new enzymes found in India’s wildfire-prone areas for biorefineries

Micro-organisms found in the wildfire-prone rainforests of India are an exciting prospect for biochemical production, as they are accustomed to the challenging conditions following a forest fire. The enzymes they produce are likely to also have a higher-than-normal resistance to the substances released from biomass in high-temperature industrial processes. An EU and nationally funded project led by VTT Technical Research Centre of Finland, called IndZyme, is looking to study whether they are capable of breaking down agricultural waste better than commercial enzymes. Converting the

Enzymatica AB: Interim report for Enzymatica AB (publ) January-September 2017

Interim report forEnzymatica AB (publ)                                                                                                                                                                             January-September 2017Sales soar in third quarter Q3              · Net sales reached SEK 24.8 (11.9) million. · Loss after tax came in at SEK -3.6 (-6.5) million. · Earnings per share, basic and diluted, were SEK -0.04 (-0.08). · Cash and cash equivalents were SEK 9.5 (49.9) million. Significant events in Q3 · German STADA's order from Q2 for SEK 12

Hexagon Composites ASA: Results for the third quarter 2017

In the third quarter 2017 Hexagon Composites generated NOK 352.8 (266.2) million in operating income and made an operating profit before depreciation and amortization (EBITDA) of NOK 51.2 (4.6) million. Operating profit (EBIT) was NOK 33.8 (-12.4) million and profit before tax came to NOK 21.8 (-18.4) million. Overall, Group operating profit has markedly improved versus the third quarter 2016, and the previous quarter. Operating results in the third quarter were impacted positively by a 32% growth in revenues versus the same period last year. Both the Low-Pressure and High-Pressure

Lundbeck and Otsuka will initiate a third phase III trial to evaluate the use of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type

Valby, Denmark and Tokyo, Japan, 1 November 2017 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce that the two companies will initiate a third clinical phase III study for brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type. The trial is expected to commence during the first half of 2018.  The decision to initiate a third trial follows discussions with the U.S. Food and Drug Administration (FDA) in October regarding the two, completed phase III clinical trials for the agitation indication that were completed by

Nokian Tyres plc Interim Report January–September 2017: Strong performance with solid full year expectations

Nokian Tyres plc Interim Report January–September 2017, November 1, 2017, 8:00 a.m. This release is a summary of Nokian Tyres’ Interim Report January–September 2017. The complete report is attached to this release. It is also available on the company website at www.nokiantyres.com/company/investors/. July–September 2017 · Net sales increased by 14.5% to EUR 363.1 million (317.2 in 7–9/2016). Currency exchange rate changes affected net sales negatively by EUR 0.2 million compared with the rates in 7–9/2016. · Operating profit increased by 21.3% to EUR 89.8 million (74.1).

There are no items matching the current filter
There are no more items matching the current filter
Back to top